Ratings by BofA Securities (Graham Perry)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/12/2026 | Sanofi | SNY | Downgrade | Neutral (Buy) |
49.25 (40.61) |
-17.54% | Details | |
| 11/25/2025 | GlaxoSmithKline | GSK | Upgrade | Neutral (Underperform) |
47.19 (49.51) |
4.92% | Details | |
| 9/11/2024 | Novartis | NVS | Downgrade | Neutral (Buy) |
117.16 (150.62) |
28.56% | Details | |
| 10/4/2023 | Novartis | NVS | Maintain | Buy (N/A) |
|
Details | ||
| 12/5/2022 | GlaxoSmithKline | GSK | New Coverage | Underperform (N/A) |
35.35 (47.19) |
33.49% | Details | |
| 9/10/2018 | Genmab | GMXAY | Downgrade | Underperform (Buy) |
16.49 (18.35) |
11.28% | Details | |
| 9/10/2018 | Roche | RHHBY | Downgrade | Neutral (Buy) |
30.47 (57.14) |
87.53% | Details | |
| 9/10/2018 | Sanofi-Aventis | SNY | Upgrade | Buy (Neutral) |
42.14 (49.25) |
16.87% | Details | |
| 9/10/2018 | Novartis | NVS | Upgrade | Buy (Neutral) |
81.78 (150.62) |
84.18% | Details |
